Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973

Next Previous
Trial Profile

An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Praliciguat (Primary) ; Itraconazole
  • Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension in diabetes; Pulmonary arterial hypertension
  • Focus Pharmacokinetics
  • Sponsors Ironwood Pharmaceuticals

Most Recent Events

  • 19 Jul 2018 Status changed from active, no longer recruiting to completed.
  • 07 Jun 2018 Planned End Date changed from 2 Jul 2018 to 9 Jul 2018.
  • 07 Jun 2018 Planned primary completion date changed from 2 Jul 2018 to 9 Jul 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top